Airware Labs Announces Name Change to Item 9 Labs Corp. and New Ticker Symbol "INLB"

SCOTTSDALE, Ariz., April 26, 2018 -- Airware Labs Corp (OTC:AIRW) (“Airware” or the “Company”), is pleased to announce that today the Financial Industry and Regulatory Authority (“FINRA”) has approved the Company’s previously announced name change to Item 9 Labs Corp., reflecting the Company’s new business direction within the Cannabis Bio-Medical industry, and a ticker symbol change. Effective on the open of markets April 27, 2018, the Company’s name will be Item 9 Labs Corp. and will trade under the ticker symbol 'INLB.'

The corporate name change was taken pursuant to the Company’s acquisition of BSSD Group, LLC, an Arizona limited liability company, doing business as Item 9 Labs, which was completed on March 21, 2018. In conjunction with the acquisition, Airware closed on a material definitive financing agreement in the principal amount of $1.09 million.

Bryce Skalla, Co-Founder & CEO of Item 9 Labs, commented, “Today’s announcement marks a key milestone in the Company’s strategy to focus its operations on the Cannabis Bio-Medical space. Item 9 Labs is dedicated to creating cannabis health solutions that deliver the industry’s highest-quality, medical-grade medical marijuana in today’s most advanced delivery platforms. We are in a strong position to enter the high-growth Cannabis Bio-Medical market as we are now combining our superior, organically grown marijuana flower with our first proprietary delivery device, a nasal mucus-membrane delivery system. Effectively, we will be producing the industry’s first medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern consumer. We are excited about what we have already accomplished and look forward to sharing progress updates in the future.”

About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTC:INLB) is focused on the development of technology and products that administer high-quality medical marijuana through a novel, proprietary intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, the largest property in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern Cannabis consumer.

Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Media Contact:
Investor Relations:
Jeffrey Rassás
(480)463-4246 or (877)876-4868
Email: [email protected]

Investor Contact:
Scott Eckstein
KCSA Strategic Communications
[email protected]
212-896-1210